MetaCap

Viking Therapeutics (VKTX) vs Viridian Therapeutics (VRDN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Viridian Therapeutics (VRDN) has outperformed Viking Therapeutics (VKTX) over the past year, losing 1.3% versus a loss of 27.7%. Over five years, VKTX leads with a +360.4% price change compared with +63.7% for VRDN. Viridian Therapeutics is the larger company by market cap ($3.40 billion vs $3.16 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VKTX-27.70%VRDN-1.25%
+27%-17%-60%
Nov 21, 20251 yearNov 20, 2026
VKTX+339.18%VRDN+54.04%
+1485%+675%-134%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VKTX versus VRDN key metrics
MetricVKTXVRDN
Share price$24.77$29.96
Market cap$3.16B$3.40B
1-day change-4.14%-4.71%
YTD return-29.59%-3.73%
1-year return-27.70%-1.25%
5-year return+360.41%+63.72%
EPS (TTM)$-5.42$-3.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$70.85M
Revenue growth (YoY)—+23359.93%
Net income (latest FY)$-359.64M$-342.60M
Operating margin—-512.91%
Net margin—-483.57%
52-week high$43.10$34.29
52-week low$23.82$13.18
Distance from 52-week high-42.53%-12.63%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+284.82%+42.72%
Average volume5.31M2.14M
Shares outstanding127.52M113.56M
Employees74252
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VRDN has outperformed VKTX by 26.4 percentage points over the past year.

About Viking Therapeutics

VKTX stock →

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

About Viridian Therapeutics

VRDN stock →

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees

VKTX vs VRDN FAQ

Which is bigger, Viking Therapeutics or Viridian Therapeutics?

Viridian Therapeutics (VRDN) is larger, with a market capitalization of $3.40B compared with $3.16B for Viking Therapeutics (VKTX).

Which stock has performed better over the past year, VKTX or VRDN?

VRDN returned -1.25% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.

Are Viking Therapeutics and Viridian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons